Enliven Therapeutics (ELVN) Other Accumulated Expenses (2022 - 2026)

Enliven Therapeutics has disclosed Other Accumulated Expenses across 5 years of filings, most recently posting $107000.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $107000.0, down 26.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $107000.0 (down 26.71% YoY), and the FY2025 annual result was $351000.0, up 72.06% from the prior year.
• Other Accumulated Expenses came in at $107000.0 for Q1 2026 at Enliven Therapeutics, down from $351000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $548000.0 in Q1 2023 to a low of $63000.0 in Q2 2025.
• The 5-year median for Other Accumulated Expenses is $317000.0 (2023), against an average of $284285.7.
• Peak annual rise in Other Accumulated Expenses reached 72.06% in 2025, while the deepest fall reached 78.35% in 2025.
• Enliven Therapeutics' Other Accumulated Expenses stood at $447000.0 in 2022, then dropped by 18.57% to $364000.0 in 2023, then plunged by 43.96% to $204000.0 in 2024, then soared by 72.06% to $351000.0 in 2025, then tumbled by 69.52% to $107000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $107000.0 (Q1 2026), $351000.0 (Q4 2025), and $86000.0 (Q3 2025), per Business Quant data.